echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 20 billion obstructive tracheal disease drug market!

    20 billion obstructive tracheal disease drug market!

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, CDE's official website shows that Quanxin Bio's class 1 new drug QX008N injection has obtained an implied license for clinical trials and is intended to be used for the treatment of asthma and chronic obstructive pulmonary disea.


    Source: CDE official website

    QX008N injection is a TSLP monoclonal antibody, TSLP receptor (TSLPR) is a member of the hematopoietic factor receptor family and is a type I cytokine receptor prote.


    In December 2021, Tezepelumab, co-developed by Amgen and AstraZeneca, was approved by the FDA for additional maintenance therapy in children and adults with severe asthma 12 years and older, becoming the world's first approved monoclonal targeting human TSLP Antibody dru.


    At present, no drug with the same target has been approved in China, but a number of products are in the clinical sta.


    Founded in 2015, Quanxin Bio is a high-tech enterprise that develops and produces antibody drugs, focusing on the innovative development of antibody drugs for the treatment of severe chronic inflammation caused by autoimmunity and allergi.


    Quanxin Bio has some Class 1 new drugs under development

    Source: MED0 China Drug Evaluation Database

    According to the data from Min.


    Source: Minet database, CDE official website, e.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.